TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04299464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo for approximately 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773
Description: Participants will receive oral RO7017773 for approximately 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773
Description: Participants will receive oral RO7017773 for approximately 12 weeks.
Study: NCT05229601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB301001
Description: Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation.
Study: NCT06481904

Intervention type: DRUG
Intervention: TZIELD (teplizumab-mzwv)
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Study: NCT06558604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg/40mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg/40mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg/40mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: 10mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: 10mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: 10mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Product
Description: 10mg, 50mg and 100mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Product
Description: 10mg, 50mg and 100mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Product
Description: 10mg, 50mg and 100mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Oral Capsule
Description: 80mg capsules
Study: NCT06378151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TLT training
Description: Emergency clinicians assigned to the intervention group will receive the following training and resources.~1. The TLT Conversation Guide: The structured conversation guide entails discussing patients' values and goals, prognosis, and shared decision-making to use a trial of intensive care. Originally used in ICU settings, we systematically refined the guide to be used in the ED incorporating inputs from patient advisors' and emergency clinicians' inputs.~2. Clinician Training: The clinician training will include a one-hour didactic on research methodologies and serious illness communication skills, followed by a four-hour communication training with trained actors.~3. EHR Documentation: An EHR template for documenting the TLT conversation findings has been developed.~4. Intensivist Communication: A standard template to communicate the TLT conversation findings to the intensivists has been developed.
Study: NCT05132075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: JDQ443 tablets, orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel concentrated solution for infusion, intravenously administered
Study: NCT04815213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: expanded autologous bone marrow derived MSC Intravaginally
Description: Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
Study: NCT05610826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Cytoreductive surgery is an operation to remove as much tumor tissue as possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)
Description: PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Description: PRRT is a molecular targeted therapy used to treat neuroendocrine tumors (NET). Molecular targeted therapies use drugs or other substances to identify and attack cancer cells while reducing harm to healthy tissue. PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.
Study: NCT05764005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based tool (MAP- Management of Active surveillance in Prostate Cancer)
Description: A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MUSIC website
Description: Standard of care educational materials {add more detail}
Study: NCT05295784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
Study: NCT04815213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: expanded autologous bone marrow derived MSC Laporoscopic
Description: Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV
Description: Extracellular vesicles injection
Study: NCT05853705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Hearts Exercise Program
Description: The participant will either begin at the easiest variation of each strength exercise (level A), or will be placed at a specific level for each strength exercise based on their assessment with physical therapy. Participants can progress to the next level of difficulty of a specific strength exercise based on their rating of perceived exertion (RPE) with the opportunity to move to the next level if they have RPE score of 6 or less and if their heart rates are at goal. Each participant will be provided with heart rate ranges based on the heart rate reserve (HRR) method using their baseline resting and peak heart rates obtained during their cardiopulmonary exercise testing (CPET) or percent predicted heart rate based on age if CPET is not available. HRR goals will be set individually for patients and adjusted per protocol to guide effort.
Study: NCT06174428

Intervention type: DEVICE
Intervention: Oral/Throat cancer test
Description: The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.

Intervention type: DEVICE
Intervention: Oral/Throat cancer test
Description: The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.

Intervention type: DEVICE
Intervention: Oral/Throat cancer test
Description: The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
Study: NCT05295784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
Study: NCT06232018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin adhesive (Dermabond)
Description: * Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ) was applied

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skin adhesive + polyester mesh (Dermabond prineo)
Description: * Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ) was applied
Study: NCT05711381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15912
Description: Drug: HM15912 Active 0.5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15912
Description: Drug: HM15912 Active 0.5mg/kg
Study: NCT05827016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Specified dose on specified days
Study: NCT05744024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality system
Description: The intervention group 1 will be wearing the 'SyncVR' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, a controller, and a headphone. The SyncVR Relax \& Distract Application (SyncVR R\&D) will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headphones
Description: Headphones with audio. The patients will be hearing their preferred audio, chosen by patient to relaxing and to offer distraction, through headphones during wound care.
Study: NCT06089967

Intervention type: OTHER
Intervention: Medical chart review
Description: Clinical data for all enrolled patients will be abstracted from the electronic medical record. This will include but will not be limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, and disease response to treatment. Clinical data will be collected for up to one year after discontinuation of cancer immunotherapy treatment.
Study: NCT05413005

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ECP regular-intensity arm
Description: * Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week)~* Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ECP accelerated-intensity arm
Description: * Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Cryo-ECP bags infused once-a-week~* Weeks 17-24: Cryo-ECP bags infused every two weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T1DM standard of care
Description: The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T1DM standard of care
Description: The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)
Study: NCT05299242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Injection
Description: 40mg in 0.8ml preparation in vials from Fresenius Kabi Ltd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline \[0.9% NaCl\]
Study: NCT05831176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Dose 1
Description: Administered subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Dose 1
Description: Administered subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Dose 1
Description: Administered subcutaneously (SC) once weekly (QW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Dose 2
Description: Administered SC once every 2 weeks (Q2W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Dose 2
Description: Administered SC once every 2 weeks (Q2W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered SC
Study: NCT06101511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs
Description: The intervention is intraoperative ventilation using the available ventilator with individualized high PEEP titrated to the lowest ΔP with RMs. After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial
Study: NCT05711381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15912
Description: Drug: HM15912 Active 0.5mg/kg
Study: NCT05238922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered at protocol defined dose.
Study: NCT06492759

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study: NCT06295692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.
Study: NCT04370795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Post transplant immunosuppressant drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Post transplant immunosuppressant drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Conditioning drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Conditioning drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Horse -Anti-thymocyte
Description: Immune suppression conditioning drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Horse -Anti-thymocyte
Description: Immune suppression conditioning drug
Study: NCT06178848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol group
Description: During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam group
Description: The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
Study: NCT04370795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Used to prevent infection and neutropenic fevers caused by chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Used to prevent infection and neutropenic fevers caused by chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation (TBI)
Description: Conditioning (only patients in Group 1 will receive TBI)
Study: NCT06484088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frustration task
Description: The experimental manipulation for this study is the frustration task. The frustration task is designed to elicit the emotional state of frustrative non-reward (FNR). During the task, participants are asked to use button press (left or right) to alternately press one of the two doors displayed on the monitor. The task has two non-frustration blocks (Block 1 and 2) and one frustration block (Block 3). During the non-frustration blocks, participants earn money for correct press on a fixed schedule. During the frustrative block, participants will not always receive reward for correct press.
Study: NCT06493305

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurolinguistic programming
Description: In the NLP application protocol, the visual, auditory and/or tactile representation system that the woman uses most frequently will be determined. Then, using the anchoring technique, the internal reactions and external reactions created by the woman's current symptoms and emotions and thoughts regarding the urination process will be combined using the anchoring technique. Existing negative emotions will be reduced and positive emotions will be reinforced. Then, with the swish technique, the intensity of the woman's existing negative emotions will be erased from the most frequently used visual, auditory or tactile representation system. Then, taking into account the representation system that the woman uses most frequently, the belief change model will be used in her negative thoughts about the current symptom, and her negative feelings and thoughts will be replaced by positive feelings and thoughts and reinforced.
Study: NCT06015893

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Take Control
Description: A computer-delivered behavioral therapy derived from the NIAAA s self-help approach, Rethinking Drinking, developed for use in pharmacotherapy trials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take Control
Description: A computer-delivered behavioral therapy derived from the NIAAA s self-help approach, Rethinking Drinking, developed for use in pharmacotherapy trials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Weekly subcutaneous (s.c.) injections of semaglutide (or placebo) up to 2.4 mg/week or maximum tolerated dose (MTD).
Study: NCT04716569

Intervention type: DRUG
Group type: OTHER
Intervention: intranasal ivermectin spray
Description: usage of ivermectin as intranasal spray for treating early covid patiens
Study: NCT05775289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive intravenous (IV) tobemstomig for four 21-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive IV pembrolizumab four 21-day cycles
Study: NCT04716569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ivermectin spray
Description: usage of ivermectin as intranasal spray for treating early covid patiens
Study: NCT05732454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etrasimod
Description: PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks